Statements (57)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:pharmaceuticals
|
| gptkbp:atccode |
L01 XE30
|
| gptkbp:class |
BRAF inhibitor
|
| gptkbp:clinical_trial |
NCT01358075
NCT01677741 NCT02019533 NCT02159066 NCT02224781 |
| gptkbp:contraindication |
pregnancy
breastfeeding severe liver impairment hypersensitivity to dabrafenib |
| gptkbp:dosage_form |
150 mg
300 mg |
| gptkbp:drug_form |
gptkb:tablet
|
| gptkbp:effective_date |
2013-05-29
|
| https://www.w3.org/2000/01/rdf-schema#label |
Tafinlar
|
| gptkbp:ingredients |
gptkb:dabrafenib
|
| gptkbp:interacts_with |
gptkb:warfarin
other BRAF inhibitors CYP2 C19 inhibitors CYP3 A4 inducers |
| gptkbp:is_monitored_by |
cardiac function
skin reactions liver function blood counts |
| gptkbp:label |
contains dosage instructions
contains patient information leaflet contains side effects information contains storage instructions |
| gptkbp:manufacturer |
gptkb:Novartis
|
| gptkbp:marketed_as |
gptkb:Australia
gptkb:Canada gptkb:European_Union gptkb:United_States |
| gptkbp:packaging |
gptkb:bottle
blister pack |
| gptkbp:requires |
gptkb:true
|
| gptkbp:route_of_administration |
oral
|
| gptkbp:side_effect |
fatigue
headache nausea fever vomiting diarrhea rash joint pain |
| gptkbp:storage |
room temperature
keep out of reach of children protected from moisture |
| gptkbp:structure |
C23 H28 F3 N5 O3 S
|
| gptkbp:type_of_care |
important for efficacy
|
| gptkbp:used_for |
treatment of melanoma
treatment of non-small cell lung cancer |
| gptkbp:bfsParent |
gptkb:Astra_Zeneca
gptkb:Novartis |
| gptkbp:bfsLayer |
4
|